COLLABORATION
Alliance Trials, LLC (AFT) offers clinical trial investigators, pharmaceutical partners and the Alliance for Clinical Trials in Oncology institutional member network collaborative opportunities to develop and conduct trials, in addition to NCI-funded initiatives. This expands access and trial design options. AFT studies are developed by the Alliance scientific committees and are integrated into scientific goals of the committees.
Sites eligible to participate in AFT trials are members of the Alliance for Clinical Trials in Oncology network in good standing. AFT determines site-protocol matches based on previous site performance, accrual reports and results from its feasibility process. AFT invites sites that meet these criteria to participate in trials.
PARTNERSHIP LEVELS
FULL OPERATIONS |
LIMITED OPERATIONS |
AFT sponsor |
Pharmaceutical collaborator sponsor |
AFT holds IND |
Pharmaceutical collaborator holds IND (regulatory) |
AFT responsible for entire conduct of the study |
Pharmaceutical collaborator responsible for entire conduct of the study |
Site contracts are with AFT |
Site contracting responsibilities determined peragreement with collaborators |
Pharmaceutical collaborator shares in study development; provides funding, drug supply anddistribution and data submission for regulatory approval (registration trials) |
AFT responsible for AFT site selection and siteperformance monitoring, assists with patient recruitment efforts at minimum; other functions areper agreement with collaborators |
Site Identification
CRITERIA |
Overall good standing as Alliance member |
AFT reviews previous site performance and accrual |
AFT conducts feasibility process to assess site’s |
AFT invites site to participate |
DIFFERENCE BETWEEN AFT AND ALLIANCE TRIALS
AFT |
ALLIANCE |
Study Selection and Development |
|
Study design by Alliance scientific and modality committees |
Study design by Alliance scientific and modality committees |
Studies available by invitation |
Studies available through CTSU menu |
Studies open to invited sites |
Studies open to Alliance and NCTN members |
Site Selection |
|
Studies limited to selected sites with network |
Generally, studies open to all components of network |
# of sites limited based on study and funding |
|
# of sites within member network may be limited; entire network, including affiliates may not be invited |
|
Operations Systems and Partners |
|
Separate Interactive Response Technology (IRT for patient registration), Clinical Trial Management System (CTMS), AFT Medidata RAVE electronic data capture, Argus Safety System (expedited adverse event reporting), electronic Trial Master File (eTMF), AFT Biospecimen Management System |
|
Central Institutional Board Review (CIRB) (Quorum or other CIRB) |
|
Mayo Clinic Statistics and Data Center |
|
Biorepository at Washington University TBD |
|
Contracts and Funding |
|
Master Services Agreement or Clinical Trial Agreement |
|
Negotiated budget (study, patient case reimbursement, administrative site costs) |
|
Per case payment for patients and accrual and pass through costs |
|
Alliance Membership Accrual |
|
One patient intervention accrual credit toward Alliance membership recorded after network has met 15 patient treatment/intervention accruals per year (cannot use AFT accruals to make up Alliance deficiency – e.g., 15 Alliance accruals + 10 AFT accruals = 25 Alliance membership accruals; however, 10 Alliance accruals + 10 AFT accruals = 10 Alliance membership accruals) |
|